Abstract: Provided herein are novel assays for the measurement of androgens such as testosterone in a sample. The assays utilize sensitive androgen receptor mutants and have much greater sensitivity than assays based on wild-type androgen receptors. The assays of the invention can detect androgens at concentrations as low as 1 ng/dl in serum, urine, environmental samples and other samples. The invention encompasses novel assay methods as well as nucleic acid sequences, proteins, and cells. Advantageously, the assays provide a measure of physiologically relevant androgen concentrations in a sample, taking into account the presence of androgen-binding factors or anti-androgen drugs in serum.

Abstract: Provided herein are novel assays for the measurement of androgens such as testosterone in a sample. The assays utilize sensitive androgen receptor mutants and have much greater sensitivity than assays based on wild-type androgen receptors. The assays of the invention can detect androgens at concentrations as low as 1 ng/dl in serum, urine, environmental samples and other samples. The invention encompasses novel assay methods as well as nucleic acid sequences, proteins, and cells. Advantageously, the assays provide a measure of physiologically relevant androgen concentrations in a sample, taking into account the presence of androgen-binding factors or anti-androgen drugs in serum.

Abstract: In one embodiment, the application discloses a method for the prophylaxis or the treatment of a pre-cancerous lesion, including atypical intraductal breast hyperplasia, in a subject, wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising compound of the formula I.